10-Q: Akari Therapeutics Reports Third Quarter 2024 Results, Announces Merger Completion and Pipeline Prioritization

Akari Therapeutics reports a net loss of $16 million for the nine months ended September 30, 2024, and announces the completion of its merger with Peak Bio, along with a strategic pipeline prioritization.

Summary

• Akari Therapeutics reported a net loss of $16.019 million for the nine months ended September 30, 2024, compared to a net loss of $5.870 million for the same period in 2023.
• The company's operating expenses increased to $16.365 million for the nine months ended September 30, 2024, from $11.716 million in the same period of 2023.
• Research and development expenses totaled $5.736 million for the nine months ended September 30, 2024, up from $2.941 million in the same period of 2023, primarily due to increased manufacturing and development activities for PAS-nomacopan.
• General and administrative expenses decreased to $6.616 million for the nine months ended September 30, 2024, from $8.775 million in the same period of 2023, due to a reduction in workforce.
• The company completed a merger with Peak Bio on November 14, 2024, expanding its pipeline to include ADC technology and a neutrophil elastase inhibitor.
• Akari's cash balance was $2.246 million as of September 30, 2024, which is not sufficient to fund operations for the next year, raising substantial doubt about the company's ability to continue as a going concern.
• The company has implemented a restructuring plan, including a 67% reduction in workforce, to reduce operating costs.
• The company issued 24,289,231,523 ordinary shares as of September 30, 2024, up from 13,234,315,298 at the end of 2023.

Sentiment

Score: 3

Explanation: The document presents a mixed picture with significant financial losses and going concern issues, offset by strategic moves like the merger and pipeline prioritization. The overall sentiment is negative due to the financial instability and need for further capital.

Positives

• The merger with Peak Bio expands Akari's pipeline with promising ADC technology and a neutrophil elastase inhibitor.
• The company has prioritized its pipeline, focusing on the PAS-nomacopan GA program and ADC platform.
• General and administrative expenses have decreased due to the restructuring and reduction in workforce.
• The company has regained compliance with Nasdaq's minimum shareholders' equity requirement.

Negatives

• The company reported a significant net loss of $16.019 million for the nine months ended September 30, 2024.
• The company's cash balance of $2.246 million as of September 30, 2024, is insufficient to fund operations for the next year.
• The company has suspended its HSCT-TMA program due to cost and timeline concerns.
• There is substantial doubt about the company's ability to continue as a going concern.

Risks

• The company faces substantial doubt about its ability to continue as a going concern due to insufficient cash reserves.
• The company is dependent on raising additional capital to fund its operations and development programs.
• There is a risk that the company may not be able to obtain additional funding on acceptable terms.
• The company's future success depends on the successful development and commercialization of its product candidates.
• The company is subject to risks associated with clinical trial outcomes and regulatory approvals.
• The company may face competition from larger, better-capitalized companies.

Future Outlook

The company expects its existing cash, plus cash from the November 2024 Private Placement, to be sufficient to fund operations into the first quarter of 2025. The company plans to focus on the PAS-nomacopan GA program and the ADC platform following the merger with Peak Bio. The company will continue to seek additional funding through financings of equity and/or debt securities, strategic collaborations, and other strategic alternatives.

Management Comments

• Management is currently evaluating different strategies to obtain the required funding for future operations.
• Management has determined that it is not more likely than not that the Company will realize these future tax benefits.
• Management believes PAS-nomacopan may be more efficacious than marketed treatments for GA that only inhibit complement.
• Management believes nomacopan may be able to prevent inflammatory and prothrombotic activities of two important pathways.

Industry Context

The biotechnology industry is characterized by high risk and high reward, with companies often facing significant losses and the need for substantial capital investment. Akari's focus on autoimmune and inflammatory diseases aligns with a growing area of unmet medical need, but the company faces competition from larger, better-capitalized companies. The merger with Peak Bio is a strategic move to diversify the pipeline and potentially enhance the company's value proposition.

Comparison to Industry Standards

• Akari's financial results are not unusual for a clinical-stage biotechnology company, which typically incurs significant losses while developing its product pipeline.
• The company's cash burn rate is a concern, as it is not sufficient to fund operations for the next year, which is a common challenge for companies in this sector.
• The restructuring and reduction in workforce are typical responses to financial pressures and pipeline prioritization in the biotech industry.
• The merger with Peak Bio is a strategic move to diversify the pipeline, which is a common strategy for companies seeking to enhance their value proposition.
• The company's focus on complement and LTB4 pathways is aligned with current trends in immunology and inflammation research.
• The development of PAS-nomacopan for geographic atrophy is a competitive area, with several other companies also developing treatments for this condition, including Apellis Pharmaceuticals with Syfovre and Iveric Bio with Izervay.

Management Changes

Related Party Transactions

• The company leases office space from The Doctors Laboratory (TDL), where a former director is CEO and the chairman is also a non-executive director.
• The company received laboratory testing and administrative services from TDL.
• The company entered into an Interim CEO Agreement with Dr. Patel, who is also a director, for compensation in the form of fully vested ordinary shares and stock options.
• The company entered into convertible promissory notes with existing investors and directors, Dr. Prudo and Dr. Patel.

Stakeholder Impact

• Shareholders face significant risk due to the company's financial instability and potential dilution from future equity financings.
• Employees have been impacted by the restructuring and reduction in workforce.
• Customers and suppliers may be affected by the company's financial challenges and potential changes in operations.
• Creditors face increased risk due to the company's going concern issues.

Next Steps

• The company will focus on the development of PAS-nomacopan for geographic atrophy and the ADC platform acquired through the merger.
• The company will seek to partner/collaborate and license opportunities for PHP-303.
• The company will pursue external partnering/collaboration and licensing for nomacopan.
• The company will continue to seek additional funding through financings of equity and/or debt securities.
• The company expects to file an Investigational New Drug Application (IND) with the FDA in 2025 for PAS-nomacopan in GA.

Key Dates

Keywords

Akari Therapeutics, Peak Bio, Merger, ADC, PAS-nomacopan, Geographic Atrophy, HSCT-TMA, Biotechnology, Clinical Trials, Financial Results, Restructuring, Warrants, Equity Financing